Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094762 | 0.71 | KDM4E (0.33) | — | |
| SCHEMBL12744505 | 0.66 | ERBB2 (0.40) | PIM1ERBB2HKDC1 | |
| SCHEMBL12440728 | 0.64 | — | — | |
| SCHEMBL4459202 | 0.61 | TSHR (0.45) | PIM1NUAK1IGF1RMETSRC | |
| SCHEMBL14067035 | 0.60 | ERBB2 (0.36) | PIM1ERBB2HKDC1 | |
| SCHEMBL6906681 | 0.60 | ALOX5 (0.41) | PIM1NUAK1IGF1RMETSRC | |
| SCHEMBL16597206 | 0.59 | ERBB2 (0.39) | PIM1ERBB2HKDC1 | |
| SCHEMBL13025134 | 0.58 | KDM4E (0.37) | PIM1ERBB2HKDC1 | |
| SCHEMBL8351615 | 0.56 | KDM4E (0.35) | PIM1ERBB2HKDC1 | |
| SCHEMBL10000754 | 0.56 | AKR1B1 (0.36) | PIM1ERBB2HKDC1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207229-B1 | Preparation of hydroquinone amide compounds with antioxidant properties | CATALYS SAS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-8207229-B1 | Preparation of hydroquinone amide compounds with antioxidant properties | CATALYS SAS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-8003824-B2 | Preparation of hydroquinone amide compounds with antioxidant properties | CATALYS SAS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-8003824-B2 | Preparation of hydroquinone amide compounds with antioxidant properties | CATALYS SAS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20110021820-A1 | Preparation of Hydroquinone Amide Compounds with Antioxidant Properties | CATALYS SAS (FR) | 2011-01-27 | — | — | US | disclosed |
| US-20110021820-A1 | Preparation of Hydroquinone Amide Compounds with Antioxidant Properties | CATALYS SAS (FR) | 2011-01-27 | — | — | US | disclosed |
| WO-2009115707-A2 | PREPARATION OF HYDROQUINONE AMIDE COMPOUNDS WITH ANTIOXIDANT PROPERTIES. | CATALYS SAS (FR) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021820-A1 | Preparation of Hydroquinone Amide Compounds with Antioxidant Properties | NQO1, TYR, AHR | PIM1 4108/4885ERBB2 2837/4885HKDC1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.